tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tang S and Lai KN Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft. 2005 Am. J. Kidney Dis. pmid:15806458
Rao PS Nephrotic syndrome in patients with peripheral blood stem cell transplant. 2005 Am. J. Kidney Dis. pmid:15806483
de Mattos AM et al. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. 2000 Am. J. Kidney Dis. pmid:10676738
Kooman JP et al. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. 2001 Am. J. Kidney Dis. pmid:11382685
Choudhry S et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. 2009 Am. J. Kidney Dis. pmid:19268410
Birdwell KA et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. 2009 Am. J. Kidney Dis. pmid:19185404
Haas M et al. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. 1999 Am. J. Kidney Dis. pmid:10401019
Wong TY et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. 1999 Am. J. Kidney Dis. pmid:10585325
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Hricik DE Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583939
Pescovitz MD and Govani M Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583940
Tang S et al. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. 2003 Am. J. Kidney Dis. pmid:14582073
Pham PT et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. 2000 Am. J. Kidney Dis. pmid:11007689
Revelo MP et al. A 14-year-old boy with kidney allograft failure in the first month after transplantation. 2000 Am. J. Kidney Dis. pmid:11007695
Vischini G et al. Increased plasma levels of tacrolimus after ingestion of green tea. 2011 Am. J. Kidney Dis. pmid:21787983
van Duijnhoven EM et al. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. 2002 Am. J. Kidney Dis. pmid:12087579
Moes AD et al. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. 2017 Am. J. Kidney Dis. pmid:28259499
Wong KM et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. 2000 Am. J. Kidney Dis. pmid:10739787
Böhmig GA et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. 2000 Am. J. Kidney Dis. pmid:10739788
Starzl TE et al. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. 1998 Am. J. Kidney Dis. pmid:9631858
Lum EL et al. Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma. 2017 Am. J. Kidney Dis. pmid:28189378
Neylan JF et al. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. 1998 Am. J. Kidney Dis. pmid:9820446
Chen W et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. 2011 Am. J. Kidney Dis. pmid:21177013
First MR Renal transplantation for the nephrologist: new immunosuppressive drugs. 1992 Am. J. Kidney Dis. pmid:1371201
Paoletti E et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. 2007 Am. J. Kidney Dis. pmid:17591533
Mertz D et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. 2009 Am. J. Kidney Dis. pmid:19346040
Israni A et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. 2002 Am. J. Kidney Dis. pmid:11877596
Soi V et al. Altered mental status in a kidney transplant recipient receiving tacrolimus. 2008 Am. J. Kidney Dis. pmid:18155524
Reese PP et al. Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27940063
Tsinalis D et al. Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. 2002 Am. J. Kidney Dis. pmid:12200824
Asif A et al. Peritoneoscopic placement of peritoneal dialysis catheter and bowel perforation: experience of an interventional nephrology program. 2003 Am. J. Kidney Dis. pmid:14655200
Grinyó JM et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. 2017 Am. J. Kidney Dis. pmid:27889299
Lien YH Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients. 2016 Am. J. Med. pmid:26714210
Bar J et al. Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience. 2003 Am. J. Med. Genet. A pmid:12476448
Perez-Aytes A et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? 2008 Am. J. Med. Genet. A pmid:18074358
Chen W et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. 2013 Am. J. Med. Sci. pmid:22627258
Hsu MS et al. Clinical features and outcome of tuberculosis in solid organ transplant recipients. 2007 Am. J. Med. Sci. pmid:17700199
Ocampo-Garza J et al. Acquired Hyperpigmentation and Cicatricial Alopecia. 2016 Am. J. Med. Sci. pmid:27524226
Chen M et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. 2010 Am. J. Med. Sci. pmid:20220333
Araujo LP et al. Interaction of the anti-inflammatory annexin A1 protein and tacrolimus immunosuppressant in the renal function of rats. 2010 Am. J. Nephrol. pmid:20484890
Ferreira A et al. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. 2017 Am. J. Nephrol. pmid:28511172
Issa N et al. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. 2013 Am. J. Nephrol. pmid:23796509
Vural A et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. 2005 May-Jun Am. J. Nephrol. pmid:15925859
Li J et al. Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. 2013 Am. J. Nephrol. pmid:23689735
Lee CT et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. 2011 Am. J. Nephrol. pmid:21691056
Soubhia RM et al. Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. 2005 Jul-Aug Am. J. Nephrol. pmid:15976495
Dai DS et al. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury. 2015 Am. J. Nephrol. pmid:26439819
El-Dahshan KF et al. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. 2006 Am. J. Nephrol. pmid:16804292
Jin J et al. Klotho Deficiency Aggravates Tacrolimus-Induced Renal Injury via the Phosphatidylinositol 3-Kinase-Akt-Forkhead Box Protein O Pathway. 2016 Am. J. Nephrol. pmid:27174564
Weir MR et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. 2004 Jul-Aug Am. J. Nephrol. pmid:15237243